NCT00838383 - Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Cardiac Surgery SubjectsSubjects Undergoing CABG and/or Cardiac Valve Replacement

Interventions

DRUG

sitaxsentan (Thelin)

sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.

DRUG

sitaxsentan (Thelin)

Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.

DRUG

Placebo

Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.

Trial Locations (3)

University of Pennsylvania,, Philadelphia

Medical University of South Carolina, Charleston

The Chattanooga Heart Institute, Chattanooga